Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer, Merck & Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their...
Federal regulators have approved the first biosimilar drug to be sold in the U.S., a move that could lower treatment costs as biosimilars compete with what historically had been more expensive medications.
Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday.
Drugmaker Hospira said Wednesday that it received a warning letter from the Food and Drug Administration regarding poor manufacturing quality at one of its facilities in Australia.
Healthcare supply, analytics and consulting company Premier agreed Tuesday to acquire TheraDoc, a clinical surveillance software company, for $117 million, augmenting Premier's already sizable footprint in the clinical-safety solutions market.
Pharmaceutical and medical-device maker Hospira saw its earnings soar in the second quarter of 2014, thanks mostly to large sales of drugs that have been in short supply.
The American Hospital Association is pushing the Food and Drug Administration to be more aggressive in getting manufacturers of saline and other IV fluids to increase production to alleviate shortages.
A worsening shortage of IV saline solution, one of the most common products used in hospitals, is causing concern among healthcare providers having trouble locating saline products during this increasingly severe flu season.
The FDA is releasing a strategic plan to address the underlying causes of drug shortages, and will launch a new mobile app to alert relevant stakeholders when shortages occur.
ActiveCare, which provides remote health monitoring for diabetes and chronic disease management, has named Jonathan Olson its chief technology officer.
Tim Weaver, an 18-year-old college student who lives in Naperville, Ill., is one of the estimated 30,000 people in the U.S. who rely on intravenous nutrition products to keep them alive.
Hospira successfully fought off a government request for more details about its prolonged efforts to fix safety problems, a win that highlights the scrutiny of CEO F. Michael Ball's efforts to boost production at the giant medical products maker.